Perspective Therapeutics, Inc.
CATX NYSE
SEC CIK 728387
Follow Perspective Therapeutics
Weekly email: filings, results
Net income
−$32.4M
−24.9% vs same quarter last year
EPS, diluted
−$0.27
+22.9% vs same quarter last year
Operating cash flow
−$31.4M
−92.4% vs same quarter last year
Operating income
−$34.3M
−23.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$103.1M |
| FY24 | - | −$79.3M |
| FY23 | $1.4M | −$46.5M |
| FY22 | $0 | −$7.3M |
| FY21 | $10.1M | −$3.4M |
| FY20 | $9.7M | −$3.4M |
| FY19 | $7.3M | −$5.1M |
| FY18 | $5.9M | −$6.7M |
| FY17 | $4.8M | −$6.2M |
| FY16 | $4.8M | −$4.7M |
| FY15 | $4.6M | −$3.7M |
| FY14 | $4.2M | −$6M |
| FY13 | $4.5M | −$3.9M |
| FY12 | $5.1M | −$3.5M |
| FY11 | $5.2M | −$2.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | 100% | −2855% | −3243.2% |
| FY22 | - | - | - |
| FY21 | 50.9% | −34.3% | −33.7% |
| FY20 | 52.9% | −35.9% | −35.6% |
| FY19 | 41.7% | −71.8% | −70.3% |
| FY18 | 31.1% | −113.6% | −113.1% |
| FY17 | 17.6% | −132.5% | −129.4% |
| FY16 | 2.7% | −106.6% | −98.8% |
| FY15 | 3.6% | −94.2% | −79.9% |
| FY14 | −4.7% | −108.7% | −141.2% |
| FY13 | 3.3% | −89.9% | −85.2% |
| FY12 | 13.9% | −71% | −68.8% |
| FY11 | 22.1% | −56.6% | −54.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$95.2M |
| FY24 | −$72.7M |
| FY23 | −$38M |
| FY22 | −$8M |
| FY21 | −$3.2M |
| FY20 | −$3.9M |
| FY19 | −$5.5M |
| FY18 | −$6M |
| FY17 | −$6.3M |
| FY16 | −$4.4M |
| FY15 | −$3.7M |
| FY14 | −$3.2M |
| FY13 | −$3.1M |
| FY12 | −$2.5M |
| FY11 | −$2.6M |
- Perspective Therapeutics
- Healthcare median
Show the numbers
| Year | Perspective Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | −3243.2% | −58% |
| FY22 | - | −80.4% |
| FY21 | −33.7% | −71.9% |
| FY20 | −35.6% | −62.2% |
| FY19 | −70.3% | −46.3% |
| FY18 | −113.1% | −49.6% |
| FY17 | −129.4% | −45.9% |
| FY16 | −98.8% | −36% |
| FY15 | −79.9% | −38.4% |
| FY14 | −141.2% | −35.5% |
| FY13 | −85.2% | −37.1% |
| FY12 | −68.8% | −29.1% |
| FY11 | −54.3% | −27.9% |